ArticlePloS one2012
Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists.Journal of medicinal chemistry · 2024Article
- NOD2 Signaling Circuitry during Allergen Sensitization Does Not Worsen Experimental Neutrophilic Asthma but Promotes a Th2/Th17 Profile in Asthma Patients but Not Healthy Subjects.International journal of molecular sciences · 2022Article
- Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency.ACS medicinal chemistry letters · 2022Article
- Development of an Intranasal Gel for the Delivery of a Broadly Acting Subunit Influenza Vaccine.ACS biomaterials science & engineering · 2022Article
- A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID-19.Journal of applied microbiology · 2022Review
- Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines TheirJournal of medicinal chemistry · 2021Article
- Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation.Pharmaceutics · 2021Review
- New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses.EBioMedicine · 2020Article
- Nanoemulsion Adjuvant Augments Retinaldehyde Dehydrogenase Activity in Dendritic Cells via MyD88 Pathway.Frontiers in immunology · 2019Article
- Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulentInternational journal of nanomedicine · 2019Article
- Potential Role of Gut Microbiota in Induction and Regulation of Innate Immune Memory.Frontiers in immunology · 2019Review
- Noninvasive vaccination against infectious diseases.Human vaccines & immunotherapeutics · 2018Review
- Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity.Analytical cellular pathology (Amsterdam) · 2018Review
- Neutrophils negatively regulate induction of mucosal IgA responses after sublingual immunization.Mucosal immunology · 2015Article
- Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.Clinical and vaccine immunology : CVI · 2014Article
- Trained immunity or tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors.Clinical and vaccine immunology : CVI · 2014Article
- Meeting report VLPNPV: Session 3: Immune responses.Human vaccines & immunotherapeutics · 2014Article
- TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.Human vaccines & immunotherapeutics · 2014Article
- Norovirus Narita 104 virus-like particles expressed in Nicotiana benthamiana induce serum and mucosal immune responses.BioMed research international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Murabutide (MB) is a synthetic immunomodulator recognized by the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor on mammalian cells. MB has previously been approved for testing in multiple human clinical trials to determine its value as an antiviral therapeutic, and as an adjuvant for injected vaccines. We have found a new use for this immunomodulator; it functions as a mucosal adjuvant that enhances immunogenicity of virus-like particles (VLP) administered intranasally. MB enhanced Norwalk virus (NV) VLP-specific IgG systemically and IgA production at distal mucosal sites following intranasal (IN) vaccination. A dose escalation study identified 100 µg as the optimal MB dosage in mice, based on the magnitude of VLP-specific IgG, IgG1, IgG2a and IgA production in serum and VLP-specific IgA production at distal mucosal sites. IN vaccination using VLP with MB was compared to IN delivery VLP with cholera toxin (CT) or gardiquimod (GARD) and to parenteral VLP delivery with alum; the MB groups were equivalent to CT and GARD and superior to alum in inducing mucosal immune responses and stimulated equivalent systemic VLP-specific antibodies. These data support the further testing of MB as a potent mucosal adjuvant for inducing robust and durable antibody responses to non-replicating subunit vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.